This intervention enhanced gut barrier integrity by upregulating tight junction proteins (occludin, zonula occludens‐1 [ZO‐1]), reduced systemic LPS and TLR4/NF‐κB activation, lowered hepatic inflammatory cytokines (TNF‐α, IL‐6), and improved lipid metabolism, ultimately attenuating MASLD progression [306]. The gene discussed is NFKB1; the disease is metabolic dysfunction-associated steatotic liver disease.